| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2001;37:587.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Angiotensin II Induces Migration and Pyk2/Paxillin Phosphorylation of Human Monocytes
From the University of California Los Angeles School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes, and Hypertension, Los Angeles, Calif (U.K., S.W., S.K., W.A.H., R.E.L.); and the Department of Medicine/Cardiology, Virchowklinikum, Humboldt University Berlin and German Heart Institute Berlin (Germany) (U.K., E.F.).
Correspondence to Ronald E. Law, PhD, UCLA School of Medicine, Division of Endocrinology, Diabetes, and Hypertension, Warren Hall, Second Floor, Suite 24-130, 900 Veteran Ave, Box 957073, Los Angeles, CA 90095. E-mail rlaw{at}med1.medsch.ucla.edu
Angiotensin (Ang) II has been shown to enhance the development of atherosclerotic lesions. Migration of monocytes is an early critical step in the atherosclerotic process. To elucidate mechanisms by which Ang II promotes atherogenesis, we investigated its effects on human monocyte migration. Ang II induced migration of human peripheral blood monocytes (HPBM) and human THP-1 monocytes at concentrations between 0.01 and 1 µmol/L, with a 3.6±0.6-fold induction in HPBM and a 4.8±0.9-fold induction in THP-1 cells at 1 µmol/L Ang II (both P<0.01 versus unstimulated cells). Addition of the Ang II receptor type 1 (AT1-R) antagonist losartan (1 to 100 µmol/L) suppressed Ang II–induced migration of HPBM and THP-1 monocytes in a dose-dependent manner, demonstrating an AT1-R–mediated mechanism. Ang II–directed migration was also blocked by the Src kinase inhibitor PP2 (10 µmol/L), by the extracellular-regulated protein kinase (ERK 1/2) inhibitor PD98059 (30 µmol/L), and by the p38-MAPK inhibitor SB203580 (10 µmol/L), indicating that Src, ERK 1/2, and p38 are all involved in Ang II–induced migration of HPBM and human THP-1 monocytes. The proline-rich tyrosine kinase 2 (Pyk2) and paxillin are 2 cytoskeleton-associated proteins involved in cell movement, phosphorylated by Ang II in other cell types, and abundantly expressed in monocytes. Ang II (1 µmol/L) induced Pyk2 and paxillin phosphorylation in human THP-1 monocytes, peaking after 10 minutes for Pyk2 with a 6.7±0.9-fold induction and after 2 minutes for paxillin with a 3.2±0.4-fold induction. Ang II–induced phosphorylation of both proteins was suppressed by losartan and the Src inhibitor PP2, whereas no effect was observed with PD98059 and SB203580. This study demonstrates a novel proatherogenic action of Ang II on human monocytes by stimulating their migration, through an AT1-R–dependent process, involving signaling through Src, ERK 1/2, and p38. Furthermore, the promigratory actions of Ang II in human monocytes are associated with the phosphorylation of 2 cytoskeleton-associated proteins, Pyk2 and paxillin.
Key Words: angiotensin • monocytes • phosphorylation • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J.-L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, et al. Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites Science, July 31, 2009; 325(5940): 612 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Tchaikovski, G. Fellbrich, and J. Waltenberger The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jurewicz, D. H. McDermott, J. M. Sechler, K. Tinckam, A. Takakura, C. B. Carpenter, E. Milford, and R. Abdi Human T and Natural Killer Cells Possess a Functional Renin-Angiotensin System: Further Mechanisms of Angiotensin II-Induced Inflammation J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1093 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chon, M. C. Verhaar, H. A. Koomans, J. A. Joles, and B. Braam Role of Circulating Karyocytes in the Initiation and Progression of Atherosclerosis Hypertension, May 1, 2006; 47(5): 803 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Kim, M. Zhou, and L. M. Wahl Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture J. Leukoc. Biol., July 1, 2005; 78(1): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Shah Role of the renin-angiotensin system in the pathogenesis of preeclampsia Am J Physiol Renal Physiol, April 1, 2005; 288(4): F614 - F625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kanda, K. Hayashi, S. Wakino, K. Homma, K. Yoshioka, K. Hasegawa, N. Sugano, S. Tatematsu, I. Takamatsu, T. Mitsuhashi, et al. Role of Rho-Kinase and p27 in Angiotensin II-Induced Vascular Injury Hypertension, April 1, 2005; 45(4): 724 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nobuhiko, E. Suganuma, V. R. Babaev, A. Fogo, L. L. Swift, M. F. Linton, S. Fazio, I. Ichikawa, and V. Kon Angiotensin II Amplifies Macrophage-Driven Atherosclerosis Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2143 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, and T. Iwasaka Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 133 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Benndorf, R. H. Boger, S. Ergun, A. Steenpass, and T. Wieland Angiotensin II Type 2 Receptor Inhibits Vascular Endothelial Growth Factor-Induced Migration and In Vitro Tube Formation of Human Endothelial Cells Circ. Res., September 5, 2003; 93(5): 438 - 447. [Abstract] [Full Text] [PDF]
|
|